Private Equity Telehealth Fraud: Who Owns the Practice and Who Pays for the Orders?

Private equity telehealth fraud can involve an investor financing the marketer payments that generate prescriptions billed to the government. For someone inside a virtual-care practice, the useful questions reach from who owns the business to who approves those payments and understands what they buy. A clinician may know how an order reached the screen. An operations employee may know who funded the arrangement. Connecting those decisions to the resulting claim is central to a telehealth fraud case.

Who Owns Our Virtual Care Practice?

The professional practice may be physician-owned while a separate company manages billing, staffing and other operations. Investors can finance the business, and a technology provider can supply the platform. The name a patient recognizes may identify only part of that arrangement.

The contracts behind the practice separate those roles. A professional entity supplies the clinical assessment and treatment. A management company can supply staffing, scheduling, billing, collections, technology and marketing. For an insider who saw a payment policy imposed or a prescription questioned, we examine who had authority over that work.

How Management Contracts Divide the Work

Management contracts can put scheduling, billing and collections in a different company from the one retaining the clinician. That division matters when an employee knows who gave an instruction but the claim carries another company’s name. Teladoc’s 2025 annual filing describes physician-owned professional entities that employ or contract with providers, while Teladoc supplies exclusive nonclinical management, including billing, collections and record storage.

Amwell’s 2025 annual filing describes stock-transfer arrangements that let its board change the physician holding the professional entity’s shares. That is a concrete form of influence that a list of shareholders would leave unexplained.

We connect those contractual powers to the decision an insider describes: who could direct the work, who approved the payment and what order or claim followed. The pharmacy case below shows what alleged investor involvement can look like inside a prescription business.

What the Patient Care America Case Shows

The separate enforcement case involving Patient Care America and its private equity manager, Riordan, Lewis & Haden, concerned alleged financing of prescription kickbacks. On September 18, 2019, the Justice Department announced that the pharmacy and its private equity manager agreed to pay $21,050,000 to resolve False Claims Act allegations. The alleged payments bought a stream of prescriptions for products reimbursed by TRICARE, the federal health care program for military members and their families.

Patient Care America was the compounding pharmacy, also known as Diabetic Care Rx. Riordan, Lewis & Haden managed the pharmacy on behalf of investors. The government alleged that RLH knew of and agreed to the plan to pay outside marketers to generate prescriptions and financed those payments.

According to the Justice Department, the pharmacy paid marketers to target military members and their families for compounded pain creams, scar creams and vitamins. The products were allegedly formulated to obtain the highest possible reimbursement. The marketers paid telemedicine doctors who prescribed without seeing patients and, in some cases, without even speaking to them. The alleged arrangement left taxpayers paying for prescriptions that patients might never have discussed with a doctor.

The kickback allegations also reached patient copayments. The pharmacy and a marketer allegedly paid those amounts without checking financial need and disguised the payments through a sham charity affiliated with the marketer. The alleged arrangement financed both the referral and the patient’s share of the bill.

Patient complaints supplied another connection. The government alleged that the pharmacy continued seeking reimbursement despite regularly receiving complaints revealing prescriptions generated without consent or a valid patient-prescriber relationship. For an operations insider, the question is who received those complaints and what happened to the prescriptions afterward. The patients’ accounts could expose what the signed paperwork concealed.

Two former pharmacy employees brought the whistleblower case, and the government joined part of it. Their workplace knowledge reached the pharmacy’s reimbursement claims and the financing behind the alleged scheme.

The Staffing Fee Depended on Approval

A separate staffing settlement shows why the payment trail can reach a company that never billed Medicare. Jackson & Coker placed physicians with a telemedicine customer and earned fees when they approved prepared orders.

The settlement agreement’s admitted facts describe a $35 charge for an approved order. The staffing company’s fee depended on approval of the medical paperwork.

The telemedicine customer used information from telemarketers to prepare orders representing a treating relationship, although the settling physician neither treated nor spoke to the beneficiaries. Jackson & Coker did not itself bill Medicare. Its role concerned obtaining the orders that suppliers and laboratories used for their claims. For someone reading a staffing contract, the payment trigger can connect an administrative arrangement to the medical paperwork it produces.

What Evidence Is Needed to Report Fraud?

The evidence connects the company relationships to particular payments, orders and claims. The operating records explain who made the decisions behind the transaction.

A clinician may know what the review involved, while finance knows what the business paid for. The person overseeing marketing may know which result the contract rewarded. We work with that knowledge to connect the decisions behind prescribing to the money paid and the claims that followed.

The Patient Care America allegations put knowledge, agreement and funding together. They also put patient complaints beside continued reimbursement claims. An insider who saw those complaints reach management can help explain what the people directing the operation knew.

The 2024 Rutgers University Law Review paper Plausible Cause: Connecting the FCA and AKS in the Context of Health Care Fraud examines how to connect kickbacks to the claims they generate. It argues that companies have an evidentiary advantage because they hold their records and understand their billing processes.

The paper also points to the value of companies’ own internal analyses. Applied to an insider’s account, that means a report connecting spending to prescriptions can matter alongside the patient chart. We examine that connection with you: what the business expected its payments to produce, what orders followed and who understood the arrangement.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Our work on reporting telehealth fraud starts with the decisions and records you know, and connects them to the claim.

You Know Who Authorized the Payment

If you know how a virtual-care business approved spending, paid prescribers or handled complaints about its orders, speak to one of our whistleblower experts about how the money moved. We work beside you to build the case from the decisions you witnessed and bring in healthcare fraud whistleblower lawyers with experience in kickbacks, prescribing and investor involvement. From the first discussion through the case, we connect your knowledge of the operation to the money it caused the government to pay.